Usher Institute

RESCEU (REspiratory Syncytial virus Consortium in EUrope)

The RESCEU project aims to develop robust evidence on respiratory syncytial virus (RSV) disease burden and economic impact in Europe and provide infrastructure to perform future pivotal clinical trials for RSV vaccines and therapeutics.

RESCEU research programme logo Respiratory Syncital Virus Consortium Europe

Summary (Research in a nutshell)

Human respiratory syncytial virus (RSV) is a viral infection which can cause severe respiratory disease in the very young, elderly and in high risk groups such as premature babies or adults with chronic obstructive lung disease.

RESCEU project is an Innovative Medicines Initiative (IMI) funded project under the EU’s Horizon 2020 programme and has been funded for 5 years from 2017 to 2021. It comprises six work packages.

Using a multidisciplinary and international approach, RESCEU brings together clinicians, epidemiologists, scientists, health economists, statisticians, public health professionals, patient organisations, regulatory agencies and industry to address key gaps in knowledge of RSV. The project is timely given the many RSV vaccines and therapeutics currently under development.

Key People

Name Role
Professor Harish Nair Professor of Paediatric Infectious Diseases and Global Health, Project Coordinator
Professor Harry Campbell Professor of Genetic Epidemiology and Public Health
Rachel Reeves Research Fellow
Ting Shi Research Fellow
Anne Douglas Research Fellow
Stephanie Scott Research Assistant
You Li PhD student
Professor Steve Cunningham Professor of Paediatric Respiratory Medicine (based in Centre for Inflammation Research)
Professor Debby Bogaert Scottish Senior Clinical Fellow and Honorary Consultant in paediatric infectious diseases (based in Centre for Inflammation Research)


Professor Harish Nair:


Key publications

No publications yet.

Key Collaborations

ECDC (European Centre for Disease Control)

WHO (World Health Organisation)

GIHSN (Global Influenza Hospitalisation Surveillance Network)

RSV GEN (RSV Global Epidemiology Network)

ReSViNet (Respiratory Syncytial Virus Network)


University of Antwerp, Belgium

University Medical Centre Utrecht, Netherlands

University of Oxford, UK

Synapse Research Management Partners S.L, Spain

Imperial College of Science, Technology and Medicine, UK

Servicio Galego de Saúde, Spain

Varsinais-Suomen sairaanhoitopiirin kuntayhtymä, Finland

Rijksinstituut voor Volksgezondheid en Milieu (National Institute for Public Health and the Environment),  Netherlands

Statens Serum Institut, Denmark

Academisch Ziekenhuis Groningen, Netherlands

Fondazione PENTA, Italy

AstraZeneca AB

Pfizer Limited

GlaxoSmithKline Biologicals SA

Sanofi Pasteur

Janssen Pharmaceutica NV

Novavax Inc.


Innovative Medicines Initiative 2 Joint Undertaking

European Union’s Horizon 2020 research and innovation programme and EFPIA (Grant no. 1156019)


January 2017- December 2021


Scientific themes

Respiratory Syncytial Virus, respiratory infections, epidemiology, burden of disease, clinical trials

Methodology keywords

Systematic review, clinical trial, biobank, record-linkage, epidemiology, health economics, modelling